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Recent strategies to treat peripheral arterial disease (PAD) have focused on stem cell
based therapies, which are believed to result in local secretion of vascular growth
factors. Little is known, however, about the role of ischemic endogenous cells in this
context. We hypothesized that ischemic muscle cells (MC) are capable of secreting
growth factors that act as potent effectors of the local cellular regenerative environment.
Both muscle and endothelial cells (ECs) were subjected to experimental ischemia, and
conditioned medium (CM) from each was collected and analyzed to assess myogenic
and/or angiogenic potential. In muscle progenitors, mRNA expression of VEGF and
its cognate receptors (Nrp1, Flt, Flk) was present and decreased during myotube
formation in vitro, and EC CM or VEGF increased myoblast proliferation. Angiopoietin-
1 (Ang-1), Tie1, and Tie2 mRNA increased during MC differentiation in vitro. Exogenous
Ang-1 enhanced myogenic (MyoD and Myogenin) mRNA in differentiating myoblasts and
increased myosin heavy chain protein. Myotube formation was enhanced by MC CM and
inhibited by EC CM. Ang-1 protein was present in CM from MCs isolated from both
the genetically ischemia-susceptible BALB/c and ischemia-resistant C57BL/6 mouse
strains, and chimeric Tie2 receptor trapping in situ ablated Ang-1’s myogenic effects
in vitro. Ang-1 or MC CM enhanced myotube formation in a mixed isolate of muscle
progenitors as well as a myoblast co-culture with pluripotent mesenchymal cells (10T1/2)
and this effect was abrogated by viral expression of the extracellular domain of Tie2
(AdsTie2). Furthermore, mesh/tube formation by HUVECs was enhanced by Ang-1 or
MC CM and abrogated by Tie2 chimeric receptor trapping. Our results demonstrate
the ability of muscle and endothelial cell-derived vascular growth factors, particularly
Ang-1, to serve as multi-functional stimuli regulating crosstalk between blood vessels
and muscle cells during regeneration from ischemic myopathy.
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Introduction
Peripheral artery disease (PAD) is caused by atherosclerosis of the
peripheral arteries, most commonly in the lower extremities, and
is nearly as prevalent as coronary artery disease (CAD) (Hirsch
et al., 2006). Traditionally, research on the limb tissue response to
ischemia has focused on angiogenesis and vascular remodeling.
In addition to delivery of exogenous vascular growth factors,
therapeutic angiogenesis by targeted delivery of transduced
myoblasts has been suggested as a promising option for ischemic
muscle diseases (VonDegenfeld et al., 2003), and clinical research
has recently emphasized the development of stem or progenitor
cell therapies to stimulate angiogenesis in patients with PAD
(Prather et al., 2009; Fadini et al., 2010, 2012; Lawall et al., 2011;
Blum et al., 2012; Volz et al., 2012). In addition to stimulating
vascular growth through actions on endothelial cells (ECs), it has
been suggested that these approaches may act directly on muscle
progenitor cells (Deasy et al., 2009). Despite the identification of
skeletal muscle myopathy in the limb muscle of PAD patients
(Brass andHiatt, 2000; Brass et al., 2000, 2004; Pipinos et al., 2007,
2008), skeletal muscle is often not considered as a component of
PAD pathology. In fact, the presence of muscle degenerative and
regenerative phenotypes in both mouse hindlimb ischemia (HLI)
and human PAD are often overlooked or minimized (Yang et al.,
2008).
Skeletal muscle possesses an inherent plasticity that allows
it to recover from substantial insult. This plasticity involves
the coordination of processes involved in vascular growth
(angiogenesis) and maintenance, extracellular matrix deposition,
and nerve and muscle fiber regeneration (Charge and Rudnicki,
2004; Gehrig and Lynch, 2011; Winkler et al., 2011). Because
measures of muscle strength/integrity have been correlated
with mortality in patients with PAD (McDermott et al., 2012),
enhanced muscle regeneration in response to ischemia could
represent a potential critical source of pro-angiogenic factors
in the local ischemic limb environment. The mechanisms of
cross-talk between skeletal muscle and endothelial cells during
periods of injury and stress remain poorly defined, but may be
representative of complex and novel evolutionarily conserved
mechanisms for overall tissue survival and recovery from
pathological insults. Despite differences in the transcriptional
responses of the various cell types in regenerating skeletal muscle
tissue (Arany et al., 2008), increasing evidence demonstrates that
their responses to injury are critically linked through regulatory
factors traditionally thought to target blood vessels exclusively.
Among the early genes expressed in response to skeletal muscle
injury are several angiogenic growth factors, including vascular
endothelial growth factor (VEGF) and the angiopoietins (Ang-
1, Ang-2), and their cognate receptors (Wagatsuma, 2007). Like
VEGF, the effects of the angiopoietins are not specific for vascular
endothelial cells, as their receptors (Tie1, Tie2) are known to be
expressed in hematopoietic cells and they have also recently been
Abbreviations: MPC, muscle progenitor cell; MC, muscle cell; EC, endothelial
cell; CM, conditioned medium; HND, hypoxia and nutrient deprivation; PAD,
peripheral artery disease; CLI, critical limb ischemia; VEGF, vascular endothelial
growth factor; VEGFR, vascular endothelial growth factor receptor; Ang,
angiopoietin; HUVEC, human umbilical vein endothelial cell.
shown to be expressed in skeletal muscle cells (Chazaud et al.,
2003; Abou-Khalil et al., 2009).
The close proximity of local muscle progenitor cell
populations, including both satellite cells and pericytes, to
resident endothelial cells (Abou-Khalil et al., 2010) may facilitate
unique responses to the ischemic and myopathic environment
that exists in PAD. For example, VEGF, which is upregulated
by cellular hypoxia, is known to drive angiogenesis as well
as stimulate muscle regeneration (Germani et al., 2003; Arsic
et al., 2004; Messina et al., 2007). Accordingly, Rissanen et al.
(2002) have immunohistochemically verified that atrophic
and regenerating myofibers in patients with both acute and
chronic lower limb ischemia express not only VEGF but also
VEGF receptors. We recently demonstrated that another
angiogenic factor, Ang-1, improves muscle contractility,
myofiber regeneration, and capillary density in response to
toxin-mediated muscle injury in mice (Mofarrahi et al., 2015).
Furthermore, we co-localized Ang-1 expression to satellite cells
in the regenerating environment and verified a myogenic role for
Ang-1 in myoblast fusion. These findings suggest a novel dual
role for traditional vascular growth factors as potential myogenic
regulatory factors in limb ischemia. The local production of
these growth factors and how they modulate both myogenesis
and angiogenesis in the ischemic limb are not well understood,
but could potentially lead to the development of novel therapies
targeting the skeletal myopathy associated with critical limb
ischemia (CLI). To explore this idea, we tested the hypothesis
that vascular growth factors secreted by endothelial and muscle
cells during experimental ischemia affect both myogenesis and
angiogenesis by acting in both a paracrine and autocrine fashion
to alter muscle progenitor and endothelial cell biology.
Materials and Methods
Animals
Experiments were conducted on adult C57BL/6 and BALB/c
mice and approved by either East Carolina University or Duke
University Medical Center Institutional Animal Care and Use
Committees. All animal care complied with theGuide for the Care
and Use of Laboratory Animals, Institute of Laboratory Animal
Resources, Commission on Life Sciences, National Research
Council. Washington: National Academy Press, 1996.
RNA Isolation and RT-PCR
Total RNA was extracted using Trizol-phenol/chloroform and
reverse-transcribed using Superscript III Reverse Transcriptase
Kit and random hexamer primers (Invitrogen Inc.). Real-time
PCR was performed using a 7500 Real-Time PCR System
(Applied Biosystems, Foster City, CA). Relative quantification of
mRNA levels was determined using the comparative threshold
cycle (11CT) method using FAM TaqMan R© Gene Expression
Assays (Applied Biosystems) specific to each gene run in complex
(multiplex) with a VIC labeled GAPDH control primer.
Primary Antibodies and Materials
The following commercial antibodies were used: MyHC
(MF20, Developmental Studies Hybridoma Bank, University
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of Iowa), α-tubulin (Sigma-Aldrich), DAPI mounting medium
(VECTOR Laboratories, H-1200) and Ang-1 (AF923, R&D
Systems). Recombinant mouse Tie-2 Fc Chimera (762-T2-
100; R&D Systems), recombinant human Ang-1 (500 ng/mL;
R&D Systems), recombinant human Ang-2 (500 ng/mL;
R&D Systems), recombinant human VEGF (50 ng/mL; R&D
Systems), human basic fibroblast growth factor (5 ng/mL;
R&D Systems), and recombinant basic hepatocyte growth
factor (500 ng/mL; R&D Systems) were used in cell culture
experiments.
Immunoblotting
SDS-PAGE and WB were performed according to standard
methods. Blots were visualized with chemiluminescence using
standard film procedures. Blotting for Ang-1, specifically, was
performed as previously detailed (Davis et al., 1996). Loading and
transfer of equal amounts of protein was confirmed by Ponceau
staining and probing with anti-α-tubulin.
Cell Lines and Culture
Primary murine muscle precursor cells (mouse myoblasts)
were prepared as previously described (Rosenblatt et al.,
1995; McClung et al., 2012). Briefly, muscle cells (MCs) were
isolated from 6-week-old C57BL/6J or BALB/cJ mice, preplated
for purification, and grown in growth medium (Ham’s F10
supplemented with 20% FBS, Pen-Strep (P/S/A) and 5 ng/mL
rbasic FGF for 6 days. DMEM supplemented with 10% FBS and
P/S/A was used to maintain immortalized murine C2C12 cells,
which were purchased fromATCC. C3H-10T1/2 pluripotent cells
were purchased from ATCC and maintained in Eagle’s Basal
medium with 2mM L-glutamine, 1.5 g/L sodium bicarbonate
and Earle’s BSS supplemented with 10% heat-inactivated FBS
and P/S/A. Previously described (Misteli et al., 2010) LacZ
positive primary myoblasts from C57BL/6 mice were also
utilized for gene expression and fusion experiments. Reduced
serum medium (DMEM supplemented with 2% HoS, P/S/A,
and.1% Insulin/Selenium/Transferrin) was utilized to induce
myotube formation/differentiation. Briefly, cells were rinsed
twice in 1X phosphate-buffered saline (PBS) and returned to
standard culture conditions in differentiation medium (DM)
for the indicated times, and medium was changed every 24-
h. Human umbilical vein endothelial cells (HUVECs) were
isolated as previously described from donor placental umbilical
veins (Harfouche et al., 2003). To evaluate the effects of
ischemia/hypoxia in skeletal muscle and (ECs) in vitro, we
have established a model of cellular hypoxia in which cells
are subjected to 0.0% O2 and deprived of nutrients in Hanks’
balanced salt solution (HBSS) (Arany et al., 2008) to mimic
the local environment resulting from severe ischemia in PAD
(referred to hereafter as hypoxia+nutrient deprivation, HND).
HND was performed to generate conditioned medium (CM)
from muscle myotubes or ECs. Endothelial cell proliferation
was assessed using a hemocytometer and standard culture
techniques. Muscle myoblast cell proliferation was assessed
by methanol fixation, staining with hematoxylin, and image
analysis.
Fusion Index and EC Cord/Tube Formation Assay
For fusion index analysis, myotubes were washed with PBS,
fixed with 100% methanol for 5min, left to air dry for 10min,
permeabilized in 0.25% Triton X-100/PBS, immunofluorescently
labeled with MF-20 (Myosin) antibody overnight at 4◦C followed
by 2 rinses in PBS. Cells were then incubated with IgG2b Alexa
Fluor 488 secondary antibody for 1 h at RT, rinsed twice in PBS,
and mounted in VECTASHIELD DAPI mounting medium. All
wells within a single experiment were labeled simultaneously
using the same batch of antibody dilutions and solutions.
Each well was photographed in five randomly selected regions
using an inverted microscope camera system. The number of
myonuclei and the total number of nuclei were scored and the
fusion index was calculated as the percentage of total nuclei
incorporated in myotubes, which were defined as having > 2
nuclei. To verify the effects of exogenous Ang-1 we used an
adenoviral vector encoding soluble Tie2 (AdsTie2) (Lin et al.,
1998). Co-culture experiments were performed by plating C3H-
10T1/2 pluripotent cells at a 75–25% ratio with C2C12 myoblasts
in 6-well plates coated with entactin, collagen, laminin (ECL,
08-110 Millipore) and allowed to adhere and reach 50–60%
confluence in primary GM overnight. For the analysis of the
effects of angiopoietin-1 scavenging on co-culture fusion index,
approximately 100,000 cells at a 75/25% ratio of C3H-10T1/2
to C2C12 were plated on 12-well plates coated with ECL and
allowed to adhere and reach 50–60% confluence in primary GM
overnight, and infected with either control AdGFP, or AdsTie2
for 24 h in DM. DM was then changed every 24 h for 3-days
for a total of 96-h of differentiation. To verify the presence
and role of Ang-1 in ischemic CM we utilized a chimeric Tie2
receptor trap. Briefly, CM was incubated overnight with fcTie2
at 4◦C with rotation. IgG agarose beads were then used to
immunoprecipitate associated proteins and Ang-1 depletion was
verified by western blotting. Mesh/loop formation in HUVECS
was performed by plating approximately 15000 HUVEC cells in
each well of a Matrigel (354263, Corning) coated 48-well plate,
and incubating for 8-h at 37◦C and 5.0% CO2. Cells were then
rinsed in 1XPBS and fixed for 20min in 4% Paraformaldehyde
before phalloidin/DAPI staining and imaging on an inverted
microscope. Each well was photographed in three randomly
selected regions and the number of meshes/loops was quantified
manually.
Statistical Analysis
Statistical analyses were carried out using StatPlus:mac (v 2009)
statistical software. Data were compared using ANOVA and
Student’s 2-tailed t-test. In all cases, P < 0.05 was considered
statistically significant.
Results
Previous reports have detailed specific effects of traditional
vascular growth factors on ischemic muscle tissue. VEGF, in
particular, has been widely studied in the context of ischemic
angiogenesis in skeletal muscle tissue (Rissanen et al., 2001;
Iwaguro et al., 2002; Arsic et al., 2004; Yan et al., 2005;
Karkkainen et al., 2009; Jazwa et al., 2013), and is known
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to be produced in regenerating myofibers (Rissanen et al.,
2002). For these reasons, we initially verified the expression
of VEGF and its cognate receptors (VEGFR1/Flt, VEGFR2/Flk,
and Neuropillin/Nrp1) in differentiating muscle progenitor
cells. During myotube formation (48 and 96-h), VEGF, Nrp1,
Flt, and Flk gene expression decreased compared to that
observed in confluent myoblasts (Figures 1A–D). Primary MPC
proliferation was increased in the presence of recombinant
VEGF (Figure 1E), corroborating previously reported expression
patterns and effects of VEGF on MPCs in vitro (Germani
et al., 2003). The proliferative effect of recombinant VEGF
on MPCs was replicated with conditioned medium generated
from experimentally ischemic endothelial cells (EC CM),
but not muscle cells (MC CM) (Figure 1F), indicating the
potential for ischemic endothelial cells to drive myoblast
proliferation and subsequentmuscle regeneration in the ischemic
environment.
Similar to VEGF, angiopoietin signaling has recently been
recognized for its role as an effector of muscle cells (Abou-
Khalil et al., 2009; Lee et al., 2013; Mofarrahi et al.,
2015), and its expression in muscle progenitors and ability
to enhance muscle regeneration from toxin-induced injury
has been shown (Mofarrahi et al., 2015). The potential
paracrine influence of Angiopoietins on both muscle and
endothelial cells, therefore, makes it a viable target for
therapeutic intervention during ischemia as well. We examined
the mRNA expression patterns of the angiopoietins (Ang-
1 and Ang-2) and their cognate receptors (Tie1 and Tie2)
over the timeline of MPC differentiation. Ang-1 mRNA
increased with myotube formation (Figure 2A), while Ang-2
mRNA decreased (Figure 2B). Expression of Tie1 and Tie2
mRNA increased during myotube formation (Figures 2C,D).
Treatment of confluent myoblasts with exogenous Ang-1 for 24 h
increased mRNA expression of differentiation (p21; Figure 2E)
and myogenic regulatory factors (MyoD and Myogenin;
Figures 2F,G) and the protein expression of myosin heavy chain
(Figure 2H). These findings corroborated our previous data from
human muscle cells (Mofarrahi et al., 2015) and demonstrate
both a coordinated pattern of expression of Angiopoietin and
cognate receptor gene expression during myotube formation
and the myogenic influence conferred specifically by Ang-1.
To determine the ability of ischemic muscle or endothelial
cells to express factors that could influence myogenesis, MPCs,
and ECs were subjected to HND as a means of inducing
experimental ischemia, and effects on myotube formation were
tested. Conditioned medium from ischemic endothelial cells
(EC CM) inhibited myotube formation, whereas conditioned
medium from ischemic myotubes (MC CM) enhanced the
FIGURE 1 | Ischemic endothelial cells promote muscle precursor cell
(MPC) proliferation. (A–D) Muscle myoblasts were grown to confluence
and placed in differentiation medium (DM) for 48- or 96-h. QRT-PCR was
used to determine the mRNA expression levels of VEGF (A), Neuropilin/Nrp1
(B), VEGFR1/Flt (C), and VEGFR2/Flk (D). (E) Primary mouse MPCs were
plated at approximately 20% confluence, treated with recombinant VEGF
(50 ng/mL), and cell number was determined at the indicated time points. (F)
Primary mouse MPCs were plated at approximately 20% confluence, treated
with conditioned medium from muscle cells (MC CM) or HUVECs (EC CM)
that had been subjected to experimental ischemia (HND), and cell number
was determined at the indicated time points. Cell proliferation rates were
normalized to Control values at 24-h post-plating. *P < 0.05 vs. Myoblasts
(QRT-PCR) or time-matched control (proliferation). †P < 0.05 vs.
time-matched MC CM treatment group. All values are means ± SE.
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FIGURE 2 | Angiopoietin-1 enhances myotube formation. (A–D)
Myoblasts were grown to confluence and allowed to differentiate for 48-
or 96-h. QRT-PCR was used to determine the mRNA expression levels of
Ang-1, Ang-2, Tie1, and Tie2. (E–G) Myoblasts were grown to confluence
and allowed to differentiate for 24 h with exogenous administration of
recombinant hepatocyte growth factor (HGF; 500 ng/mL), Ang-1
(500 ng/mL), or Ang-2 (500 ng/mL). QRT-PCR was used to determine the
mRNA expression of the cell cycle regulator p21 (E) and the myogenic
regulatory factors MyoD (F) and Myogenin (G). (H) Myoblasts
differentiated for 24-h with exogenous HGF, Ang-1, or Ang-2 were
analyzed for myosin heavy chain (MyHC) protein. *P < 0.05 vs. Myoblast.
All values are means ± SE.
FIGURE 3 | Ischemic myotubes and Ang-1 promote myoblast
differentiation. (A) Representative immunofluorescently labeled images of
differentiated myotubes (96 h) for visualization of myosin heavy chain (MHC,
green) and nuclei (DAPI, blue) after treatment in differentiation medium
supplemented with 25% by volume vehicle (HBSS) or conditioned medium
from experimentally ischemic HUVECs (EC CM) or myotubes (MC CM). (B)
Quantification of the percentage of nuclei incorporated into multinucleated
myotubes (Fusion Index, %) after CM treatment. (C) Representative images
of immunofluorescently labeled differentiated myotubes (96 h) after treatment
in differentiation medium supplemented with Ang-1 (500 ng/mL), or Ang-2
(500 ng/mL) Green: myosin heavy chain (MHC); blue: DAPI. (D) Quantification
of the percentage of nuclei incorporated into multinucleated myotubes
(Fusion Index, %) after angiopoietin treatment. *P < 0.05 vs. Control or
Myoblast, †P < 0.05 vs. EC CM treatment group. All values are means ± SE.
fusion of MPCs into multinucleated myotubes (Figures 3A,B).
Interestingly, we could re-capitulate this effect by treating
differentiating myoblasts daily with exogenous recombinant
Ang-1, but not Ang-2 (Figures 3C,D).
We next sought to verify whether Ang-1 is indeed a
component of MC CM and whether its presence is required to
confer the myogenic effects of MC CM in primary cell cultures.
A mouse strain-dependent regenerative response occurs in vivo
and in vitro with HLI. Specifically, some inbred mouse strains
(e.g., BALB/c) display marked tissue necrosis in response to HLI
whereas other strains (e.g., C57BL/6) show little to no tissue
injury (Dokun et al., 2008). We previously determined that the
varied pathological responses among strains include differential
expression of the Angiopoietins and their cognate receptors in
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muscle tissue. Therefore, we also aimed to identify any differences
in Ang-1 secretion with ischemia in primary myotube cultures
from ischemia-resistant (BL6) or -susceptible (BALB/c) mice.
Western blotting revealed that Ang-1 protein was indeed secreted
into MC CM but was not differentially expressed by mouse strain
(Figure 4A). Treatment of differentiating BALB/c myoblasts
with exogenous Ang-1 or MC CM derived from either BL6
or BALB/c myotubes significantly improved myotube formation
(Figures 4B,C), suggesting the absence of strain specific deficits
in ischemic myotube Ang-1 secretion. Depletion of Ang-1
from MC CM by the addition of recombinant Tie2-Fc protein
abrogated the myogenic effects of the MC CM on primary
cultures (Figures 4D,E).
Based on these results and the fact that multiple progenitor
populations can contribute to muscle regeneration after
myopathy (Abou-Khalil et al., 2010), including Pax7+ satellite
cells and NG2+ pericytes, we next examined the myogenic
potential of Ang-1 and MC CM in co-cultures of pluripotent
cells. Mixed isolates of primary cells were prepared from
mouse skeletal muscle. Cellular heterogeneity was verified by
immunofluorescence microscopy for Pax7 and NG2 (Figure 5A)
and by Western Blotting for NG2 and SMA (Figure 5B).
Myotube formation in these mixed isolates was significantly
increased by treatment with exogenous Ang-1 (Figure 5C). In
parallel experiments, immortalized 10T1/2 mesenchymal stem
cells and C2C12 myoblasts were co-cultured at a 75/25% ratio
(10T1/2:C2C12) and induced to differentiate. Similar to the
mixed primary isolates, myotube formation in these co-cultures
was also enhanced by the addition of Ang-1 (Figure 5D).
We next verified a requirement for Ang-1 in this process by
adenoviral overexpression of the soluble extracellular domain
of Tie2 (AdsTie2) to sequester Ang-1 in the culture medium.
AdsTie2 attenuated the myogenic potential of both exogenous
rhAng-1 (Figure 5E) and MC CM (Figure 5F) in 10T1/2:C2C12
co-cultures. Collectively, these studies demonstrate that the
myogenic potential of ischemic MC CM on mixed muscle
progenitor cell populations is mediated, at least in part, by
Ang-1.
We next initiated a series of experiments to determine
whether ischemic MC CM could confer angiogenic properties
on endothelial cells and whether these angiogenic effects were
also due to the presence of Ang-1 in the CM. Using a standard
angiogenesis assay, we examined the effects ofMCCMandAng-1
depleted MC CM on HUVEC mesh/tube formation in vitro
FIGURE 4 | Angiopoietin-1 is secreted by ischemic myotubes to
promote muscle cell differentiation. (A) Western blotting of CM from
primary myotubes derived from ischemia-susceptible (BALB/c) and
ischemia-resistant (BL6) parental strains verifies the presence of Ang-1
protein. (B) Representative images of primary BALB/c muscle progenitor
cells differentiated into myotubes (96 h) after treatment in differentiation
medium supplemented with vehicle (HBSS), Ang-1 (500 ng/mL), or
conditioned medium from experimentally ischemic BALB/c myotubes (MC
CM). Green: myosin heavy chain (MHC); blue: DAPI. (C) Quantification of the
percentage of nuclei incorporated into multinucleated myotubes (Fusion
Index, %) after treatment in differentiation medium supplemented with vehicle
(HBSS), Ang-1 (500 ng/mL), or conditioned medium from experimentally
ischemic BL6 or BALB/c myotubes (MC CM). (D) To verify the presence and
role of Ang-1 in ischemic CM we utilized a chimeric Tie2 receptor trap. MC
CM was incubated overnight with fcTie2 at 4◦C with rotation. IgG agarose
beads were then used to immunoprecipitate associated proteins. Ang-1
depletion was verified by western blotting. Representative lanes: 1HBSS
Vehicle Control; 2EC CM; 3MC CM; 4fcTie2 depleted MC CM Supernatant;
5fcTie2 depleted MC CM Bead/protein aggregate; 61 ng recombinant
human Ang-1; 710 ng recombinant human Ang-1. (E) Effects of depleting
Ang-1 from MC CM on myotube formation. *P < 0.05 vs. HBSS Control.
†P < 0.05 vs. MC CM or Ang-1. All values are means ± SE.
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FIGURE 5 | Effects of Ang-1 on pluripotent cell myotube formation.
(A,B) Mixed primary isolates including peri-endothelial progenitors and MPCs
were immunofluorescently labeled (A) or western blotted (B) to verify NG2
and/or Pax7 expression to demonstrate the relative expression of NG2 and
smooth muscle actin (SMA) compared to that in immortalized C2C12
myoblasts. (C) Ang-1 effects on mixed cell isolate differentiation into
myotubes (Fusion Index, %). (D) C3H-10T1/2 pluripotent cells and C2C12
myoblasts were plated at a 75:25 ratio. Cells were allowed to adhere and
then treated with Ang-1 and analyzed for myoblast fusion rates after 120 h of
low serum culture. (E,F) Effects of inhibiting bio-available Ang-1 in MC CM
on myotube formation in C3H-10T1/2:C2C12 co-cultures. Co-cultures were
infected with either control AdGFP, or AdsTie2 for 24 h and analyzed for
myoblast fusion after a total of 120 h of reduced serum culture with Ang-1 or
MC CM supplementation. *P < 0.05 vs. Control or virus-matched Control.
†P < 0.05 vs. AdGFP MC CM. β P = 0.08 vs. AdExTEK Control. All values
are means ± SE.
(Figure 6A). As expected, tube formation was significantly
increased by exogenous Ang-1 treatment, as previously described
(Cho et al., 2004). However, MC CM also increased tube
formation, and this effect was attenuated by treatment of MCCM
with recombinant Tie2-Fc protein (Figure 6B), demonstrating
the potential for paracrine effects of ischemic muscle cells on the
surrounding vasculature.
Discussion
In this report we demonstrate that muscle and endothelial cells
exposed to experimental ischemia in vitro secrete angiogenic
factors that are capable of regulating muscle progenitor
cell proliferation and muscle progenitor and pluripotent cell
differentiation into myotubes, as well as endothelial tube
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FIGURE 6 | Conditioned medium from ischemic muscle cells
enhances endothelial cell mesh/loop formation. (A) HUVECs were
plated on Matrigel and imaged after 8-h of treatment in medium
supplemented with 25% by volume vehicle (HBSS), Ang-1 (500 ng/mL),
conditioned medium from experimentally ischemic myotubes (MC CM), or
conditioned medium from experimentally ischemic myotubes (MC CM) after
Ang-1 depletion with Tie2-Fc. (B) Analysis of mesh/loop formation. For six
replicate experiments the mean mesh/tube number was calculated from
three fields of view. *P < 0.05 vs. HBSS. † vs. rhAng1 or MC CM. All values
are means ± SE.
formation. We utilized recombinant VEGF and Ang-1, as well
as a soluble Tie2 as an Ang-1 trap to determine that Ang-1
is primarily responsible for the effects of ischemic MC CM on
myoblasts, pluripotent progenitor cells, and endothelial cells.
These findings provide biological context for our previous
observation of the expression of vascular growth factor receptors,
including Tie and VEGF receptors, on MPCs12 and our work
verifying a specific role for Ang-1 in muscle regeneration
(Mofarrahi et al., 2015). Moreover, these findings demonstrate
that these signaling pathways are a component of the cellular
tissue response to ischemic muscle injury that links endogenous
progenitors and endothelial cells.
A key component of the genetically directed response of limb
tissue to ischemia is the degenerative and regenerative response
of the skeletal muscle to the insult. We previously described a
rapid and drastic shift of skeletal muscle cells toward catabolic
and apoptotic processes when exposed to hypoxia (McClung
et al., 2012). These cell types appear individually programmed to
respond in ways that preserve vascular integrity while sacrificing
muscle cell homeostasis. Intricate coordination of the pathways
mediating muscle plasticity may be required to allow tissue
survival and facilitate recovery until blood flow can be fully
restored by angiogenesis and/or collateral vessel formation. The
individual effects ofMCCM, ECCM, and vascular growth factors
in the current study represent a pattern that stimulates cellular
proliferation (VEGF and/or EC CM) and subsequent muscle
regeneration and vascular maturation (Ang-1 and/or MC CM).
In this regard, inhibition of MC fusion by EC CM suggests that
the timing of secreted factors is absolutely critical to efficiently
direct the cellular processes enacted by ischemia. Our previous
work has also demonstrated the temporal efficiency of Ang-1 to
drive muscle regeneration in the absence of a direct ischemic
event (Mofarrahi et al., 2015). In fact, exogenous administration
of Ang-1 days after the initial injury was still sufficient to enhance
muscle recovery and improve capillary density. Dysfunctional
timing of the secretion of these factors by ischemic resident cells
could inhibit tissue recovery and exacerbate the pathology of
ischemia. Our findings demonstrate the plausibility of developing
a coordinated and sequential growth factor therapy targeting
multiple cellular compartments to enhance regeneration in the
myopathic ischemic limb.
Although Ang-1 has been shown to have effects on MPCs
(Dallabrida et al., 2005; Wagatsuma, 2007; Abou-Khalil et al.,
2009; Volz et al., 2012; Mofarrahi et al., 2015), its effects
are still somewhat controversial, and little is known about its
effects on muscle regeneration in the context of ischemia. The
angiopoietins are a unique family of growth factors (including
Ang-1-4) that have context-dependent agonist or antagonist
cellular effects despite binding Tie2 with similar affinity, and
Ang-1 and -2 have been shown to be critical for the remodeling
and maintenance of blood vessels (Fukuhara et al., 2010; Reiss,
2010). Evidence has shown that skeletal muscle cells respond
to the angiopoietins both as myoblasts and as differentiated
myotubes in a manner previously shown to be at least partly
integrin receptor-dependent (Dallabrida et al., 2005). Mature
murine myotubes display much greater responsiveness to Ang-
1 in vitro than do undifferentiated myoblasts (Dallabrida et al.,
2005). Although this difference was originally attributed to
increased integrin subunit expression with myotube maturation,
markedly greater expression of Tie2 withmyoblast differentiation
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may also be responsible for this effect (Abou-Khalil et al., 2009).
However, our results suggest that, regardless of whether Ang-1
acts through Tie2 or integrins, exogenous Ang-1 has potential
therapeutic utility for skeletal myopathies in addition to its
potential for improving vascular growth and stabilization.
Satellite cells reside in close proximity to both myonuclei and
capillary endothelial cells, and they are activated and induced to
differentiate by various growth factors, including basic fibroblast
growth factor (bFGF), insulin-like growth factor-1 (IGF-1),
hepatocyte growth factor (HGF), vascular endothelial growth
factor (VEGF), and platelet-derived growth factor (PDGF), some
of which can be expressed by endothelial cells (Christov et al.,
2007). In return, satellite cells produce endothelial growth factors
to stimulate angiogenesis and provide the new tissue with oxygen
and nutrients (Dallabrida et al., 2005; Rhoads et al., 2009; Flann
et al., 2014). It is likely that each of these individual growth factors
plays an important role in directing the cellular responses of the
local environment to ischemia. In this context, altered growth
factor expression would be regulated in a temporal manner to
direct muscle progenitor cell responses, i.e., proliferation and
differentiation. Of particular relevance to the ischemic response
are the decrease in HGF expression by muscle progenitor cells
(Flann et al., 2014) and the increase in VEGF expression by
progenitor cells and endothelial cells induced by hypoxia. HGF
is known to mediate satellite cell quiescence in a concentration-
dependent fashion (Yamada et al., 2010). In contrast, VEGF
destabilizes the endothelium and induces proliferation of both
endothelial cells and satellite cells. Reducing inhibitory stimuli
while increasing proliferative stimuli would be an evolutionarily
advantageous means of ensuring proper progenitor cell numbers
to repair the myopathy during ischemia while simultaneously
providing an angiogenic stimulus to restore proper delivery of
oxygen and nutrients. Here, and in our recent work in vivo
(Mofarrahi et al., 2015), we demonstrate that the Angiopoietin
signaling axis is an important component of the differentiation
response during skeletal muscle tissue repair. In the context of the
overall signaling network between muscle cells and endothelial
cells, Ang-1 likely represents a “maturation signal,” driving
the maturation of both nascent vascular sprouts (Fagiani and
Christofori, 2013; Qin et al., 2013) and the fusing myoblasts
involved in myofiber restoration. Thus, in addition to HGF,
VEGF, and possibly other growth factors, Ang-1 represents
another critical component of the microenvironmental response
that drives both vascular- and muscle-specific responses to
ischemia.
It is important to note that Ang-1 may have differential
effects on muscle and endothelial cells in both a concentration-
and context-dependent manner (Dallabrida et al., 2005; Abou-
Khalil et al., 2009; Fukuhara et al., 2010; Lee et al., 2013).
Angiopoietin/Tie receptor signaling in the endothelium is
known to be context-dependent (Eklund and Olsen, 2006),
thus it is possible that this ligand-receptor system could have
distinct effects on specific populations of muscle precursor cells
(i.e., quiescent, proliferating, or differentiating cells). Therefore
examining effects at different cellular developmental stages is
important to elucidate the role of Ang-1 signaling in skeletal
muscle in general and regenerating muscle specifically. In the
current study, MC CM recapitulated the effects of recombinant
Ang-1 on myotube formation, and this effect was abrogated
by depleting Ang-1 with soluble Tie2, indicating that Ang-1
secreted by ischemic muscle fibers likely plays an important role
in promoting muscle regeneration in the context of ischemic
myopathy. EC CM and VEGF promoted myoblast and EC
proliferation, but the decrease in VEGFRs in myoblasts during
differentiation is consistent with a unique temporal regulation of
effects this vascular growth factor on each cell type. Although we
previously demonstrated that Ang-1 can promote skeletal muscle
regeneration after cardiotoxin-mediated injury, the ischemic
environment may induce unique and differential responses of
endothelial and muscle cells as well as unique interactions
between them. In this regard, our current results demonstrate
an important temporal regulation of endothelial and skeletal
muscle cells’ responses to ischemia, specifically with respect to
the expression of VEGF, Ang-1, and their cognate receptors.
The ability of both ECs and muscle cells to proliferate in
response to VEGF, which is upregulated by tissue ischemia
and subsequent cellular hypoxia, facilitates the regeneration of
both cellular compartments. The up regulation of Ang-1 and
the Tie receptors coincides with a decrease in VEGF/VEGFR
expression and remodeling of both muscle cells (i.e., fusion
of myoblasts into myofibers) and endothelial cells (capillary
morphogenesis and vascular maturation) during the later phases
of muscle tissue regeneration. These findings provide important
insights into the mechanisms by which “vascular” growth factors
coordinately regulate both muscle and endothelial cell responses
and they have implications for the treatment of ischemic vascular
diseases.
Recent pre-clinical evidence supports the possibility that
genetic differences play a key role in individuals’ susceptibility to
PAD, offering an opportunity to gain mechanistic insights and to
develop novel interventions for this disease. Specifically, different
inbred mouse strains have dramatically different responses to
hind limb ischemia (HLI), a model of PAD. C57BL/6 (BL6)
mice have greater baseline collateral artery density, better limb
perfusion after HLI, and marked resistance to tissue necrosis.
In contrast, BALB/c mice suffer appreciable tissue loss after HLI
(Helisch et al., 2006; Dokun et al., 2008), which has been assumed
to be a primary vascular effect. We previously established a
strain dependent and muscle progenitor specific deficit in the
BALB/c ischemic response in vitro, which included variations
in the expression of vascular growth factors and their receptors
(McClung et al., 2012). The current study did not identify
strain specific differences in the secretion or biological activity
of Ang-1 after ischemia in myotubes in vitro. Our previous
work detailed that the exacerbated myopathy in the muscle
tissue of the genetically susceptible BALB/c mice is accompanied
by significant temporal disruptions in the cellular secretion of
vascular growth factors such as VEGF and Ang-1(McClung
et al., 2012). Temporal disruptions in growth factor release
or endogenous cell activity are known to lead to progressive
exacerbation of muscle tissue degeneration and fibrosis inmodels
of muscle insult (Sato et al., 2003; Li et al., 2004; Zhu et al., 2007).
The timing of cognate receptor expression in individual cell types
complicates this scenario, and is also disrupted in response to an
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ischemic myopathy in vivo and experimental ischemia in vitro
(McClung et al., 2012). In the current study, we established the
ability of myotubes from both genetically susceptible (BALB/c)
and protected (BL6) parental strains to secrete and/or respond to
Ang-1 in a stable and carefully controlled in vitro environment.
Further work is needed to specifically examine whether temporal
alterations in the secretion of vascular growth factors or
disruptions in the context dependent expression of their cognate
receptors in the ischemic in vivo microenvironment is sufficient
to drive the strain dependent myopathy.
A major weakness of prior progenitor cell therapies for
PAD is an incomplete understanding of the effects of ischemia
on the different cell types in skeletal muscle, including
endothelial, skeletal muscle, and progenitor cells. Given the
recent demonstration of muscle as an endocrine organ (Pedersen,
2011a,b) with the ability to induce angiogenic transcriptional
programs and respond to angiogenic factors (McClung et al.,
2012), regenerating skeletal muscle may represent a unique
source of both paracrine and autocrine factors in the local
ischemic environment of PAD (Renault et al., 2013). Systems
of cross talk between various cell types during periods of
ischemia in vivo remain poorly defined, but may represent
complex and novel evolutionarily conserved mechanisms for
overall tissue survival and recovery from ischemic insult. This
is especially true in regards to the myopathy that accompanies
limb ischemia. Here, we have identified a potential role for the
traditional vascular growth factor Ang-1 in ischemic muscle
precursor and progenitor cell biology and established the
potential autocrine/paracrine function of muscle and endothelial
cells to drive an organized temporal response to ischemic muscle
injury. This work reveals new roles for angiogenic factors in
muscle biology that could be critical to improving therapeutic
strategies for PAD.
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